Tuesday, November 12, 2024
10:38 AM EST – Oncolytics Biotech Inc : Today announced third quarter financial results and operational highlights. Highlights include BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study. Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort. Oncolytics Biotech Inc (T.ONC) shares were down one cent at 1.48.
Stocks in Play: Oncolytics Biotech Inc, Tue, 12 Nov 2024 10:42:06 EST